PCM
GHDX

Piermont Capital Management’s Genomic Health, Inc. GHDX Stock Holding History

Piermont Capital Management’s Portfolio GHDX Stock Details GHDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-4,190
Closed -$211K – 249
2018
Q2 		$211K Buy
+4,190
New +$166K 0.06% 229
2018
Q1 		– Sell
-5,990
Closed -$205K – 261
2017
Q4 		$205K Sell
5,990
-330
-5% -$10.5K 0.07% 231
2017
Q3 		$203K Buy
+6,320
New +$199K 0.07% 240

Other funds holding GHDX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Piermont Capital Management's GHDX Position: Q3 2018 in Review

Piermont Capital Management sold out of Genomic Health, Inc. (GHDX) in Q3 2018, closing a stake of 4,190 shares — an estimated $211K sold.

Piermont Capital Management first reported a position in GHDX in Q3 2017 and held it in 3 quarters. The position peaked at $211K in Q2 2018. 201 funds tracked by Wall St. Rank hold GHDX as of Q3 2018.

  • Piermont Capital Management reported no remaining Genomic Health, Inc. position as of Q3 2018 after selling out during the quarter.
  • Piermont Capital Management sold 4,190 Genomic Health, Inc. shares in Q3 2018, an estimated $211K.
  • Piermont Capital Management first reported a position in Genomic Health, Inc. in Q3 2017 and held it in 3 quarters.
  • Piermont Capital Management's Genomic Health, Inc. position peaked at $211K in Q2 2018.
  • 201 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q3 2018.

Based on Piermont Capital Management's 13F filing for Q3 2018, filed 6 Nov 2018.